MRI 유도 신경외과적 절제술 시장 : 기술 유형별, 시술 유형별, 시술 목적별, 용도별 시장 예측(2026-2032년)

The MRI Guided Neurosurgical Ablation Market is projected to grow by USD 1,268.99 million at a CAGR of 8.29% by 2032.

MRI guided neurosurgical ablation is redefining functional neurosurgery, neuro-oncology, and epilepsy care by combining stereotactic targeting with real-time magnetic resonance imaging and thermal monitoring. The field includes laser interstitial thermal therapy, often called LITT, and MRI guided focused ultrasound, both of which enable precise lesioning while reducing the need for large craniotomies in selected patients.

Demand is anchored in measurable clinical need. The World Health Organization reports that epilepsy affects around 50 million people worldwide, Parkinson disease affected more than 8.5 million people in 2019, and GLOBOCAN 2022 recorded more than 300,000 new brain and central nervous system cancer cases globally. These disease burdens support sustained interest in minimally invasive neurosurgical ablation technologies that can improve procedural precision, recovery profiles, and care pathways for complex neurological conditions.

Transformative Shifts in the Neurosurgical Ablation Landscape

The landscape is shifting from exposure-heavy neurosurgery toward image-guided, incision-sparing intervention. MRI thermometry allows clinicians to visualize temperature changes during ablation, improving procedural control and supporting protection of eloquent brain structures. This capability is especially important in deep-seated lesions, drug-resistant epilepsy foci, tremor pathways, and movement disorder targets where millimetric accuracy is critical.

Adoption is also being shaped by higher-field MRI availability, stereotactic robotics, improved laser fiber and transducer designs, and hospital priorities around shorter recovery times. Payers and health systems are increasingly evaluating ablation through measurable outcomes such as seizure reduction, tremor control, length of stay, complication rates, neurocognitive preservation, and retreatment requirements.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence every phase of MRI guided neurosurgical ablation, from patient selection to treatment planning and post-procedure surveillance. AI-enabled segmentation can help identify lesion boundaries, vascular structures, white matter tracts, and thermal-risk zones, while predictive models may support trajectory planning, ablation-volume estimation, and follow-up imaging assessment.

The impact is cumulative rather than isolated. As the U.S. Food and Drug Administration list of AI and machine learning-enabled medical devices has expanded rapidly, with radiology representing the largest category, neurosurgical teams are gaining access to increasingly mature image-analysis tools. However, clinical adoption depends on validation, explainability, cybersecurity, workflow integration, and evidence that AI improves safety, reproducibility, or patient outcomes in MRI guided neurosurgical ablation.

Key Regional Insights Across Major Markets

North America remains a leading region for MRI guided neurosurgical ablation due to advanced hospital infrastructure, high MRI capacity, active academic neurosurgery programs, and established regulatory pathways for technologies such as LITT platforms and MRI guided focused ultrasound systems. The United States anchors regional adoption through specialized epilepsy, neuro-oncology, and movement disorder centers, while Canada supports evidence-based use within publicly funded care models.

Europe shows strong adoption potential through specialized neurosurgical centers, robust clinical research networks, and broad access to advanced neuroimaging; however, implementation is influenced by EU Medical Device Regulation requirements, reimbursement variability, and health technology assessment standards. Asia-Pacific is gaining momentum as Japan, China, South Korea, India, and Australia expand advanced imaging, oncology, epilepsy, and movement disorder programs, supported by rising investment in tertiary neuroscience infrastructure. Latin America is developing through private tertiary hospitals and major academic centers in Brazil and Mexico, although access remains uneven across public systems and rural populations. The Middle East, particularly high-income Gulf countries, is investing in high-acuity neuroscience infrastructure and medical travel retention, while Africa faces MRI access constraints that make regional centers of excellence essential for broader availability of MRI guided neurosurgical ablation.

Key Group Insights for Strategic Market Positioning

Across ASEAN, growth is supported by expanding private hospitals, medical tourism, and neurosurgical modernization in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, although procedure availability depends on trained specialists, MRI capacity, and referral pathways. The GCC is positioned as a premium adoption cluster because national health strategies in Saudi Arabia, the United Arab Emirates, Qatar, and neighboring markets prioritize advanced tertiary care, neuroscience centers, and reduced outbound medical travel.

The European Union offers a large, highly regulated clinical environment with strong research networks, cross-border evidence generation, and centralized procurement in many health systems, while BRICS countries combine substantial neurological disease burden and large patient populations with uneven infrastructure and reimbursement maturity. G7 markets generally lead in clinical evidence generation, reimbursement assessment, regulatory oversight, and academic adoption of MRI guided neurosurgical ablation. NATO countries benefit from advanced hospital systems, technology interoperability, and established neuroscience research capacity, particularly where trauma, rehabilitation, and complex neurosurgical services strengthen broader neurological care ecosystems.

Key Country Insights in MRI Guided Neurosurgical Ablation

The United States leads commercialization through academic medical centers, private hospital systems, FDA-cleared platforms, and high procedural specialization across epilepsy surgery, neuro-oncology, and functional neurosurgery, while Canada emphasizes evidence-based adoption within publicly funded care. Mexico and Brazil show growing demand in major urban centers, particularly where private insurers, specialist hospitals, and tertiary academic institutions support advanced neurosurgical procedures.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine sophisticated neuroimaging, established neurosurgical training, and strong clinical research capacity, while Russia has selective adoption through major federal and urban centers with advanced imaging infrastructure. China is scaling advanced neurosurgery rapidly through large hospital networks and expanding MRI capacity, India has high unmet neurological need and expanding private-sector capability, Japan and South Korea benefit from technology-intensive healthcare systems and strong imaging infrastructure, and Australia supports adoption through specialized centers serving a geographically dispersed population with complex referral needs.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical evidence that compares MRI guided neurosurgical ablation with open surgery, radiosurgery, deep brain stimulation, and medical management for well-defined indications. Evidence packages should include seizure outcomes, tremor scores, tumor control indicators where relevant, length of stay, neurocognitive outcomes, adverse events, patient-reported outcomes, and total cost of care.

Commercial strategy should focus on multidisciplinary centers that combine neurosurgery, neuroradiology, epilepsy monitoring, neuro-oncology, radiation oncology, and movement disorder expertise. Technology developers and service providers should also invest in physician training, MRI compatibility support, service uptime, reimbursement dossiers, AI validation, cybersecurity readiness, and patient-selection tools that help hospitals build safe, repeatable MRI guided neurosurgical ablation programs.

Research Methodology

This executive summary is developed using a structured secondary research approach. Inputs include peer-reviewed neurosurgery and neuroradiology literature, regulatory databases, publicly available device-clearance information, hospital adoption patterns, disease-burden data from the World Health Organization and GLOBOCAN, and policy context from regional health authorities.

Insights are triangulated across clinical evidence, technology readiness, reimbursement dynamics, regulatory context, and infrastructure indicators such as MRI availability and tertiary neurosurgery capacity. The methodology avoids unsupported market-size claims and emphasizes verified trends, documented disease burden, regulatory status, clinical-use patterns, and observable adoption drivers across regions, economic groups, and major countries.

Conclusion

MRI guided neurosurgical ablation is moving from specialized innovation to a strategic capability in advanced neuroscience care. Its value proposition is strongest where precise targeting, real-time thermal feedback, shorter recovery, and reduced surgical exposure align with clinical needs in epilepsy, brain tumors, and movement disorders.

Future progress will depend on evidence quality, reimbursement confidence, center-level expertise, MRI access, and integration with AI-enabled imaging workflows. Organizations that combine clinically validated technology, disciplined training, regional access strategies, and outcome-driven commercialization will be best positioned in the evolving MRI guided neurosurgical ablation landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. MRI Guided Neurosurgical Ablation Market, by Technology Type

• 7.1. MRI-Guided Laser Ablation
• 7.2. MRI-Guided Radiofrequency (RF) Ablation
• 7.3. MRI-Guided Focused Ultrasound

8. MRI Guided Neurosurgical Ablation Market, by Procedure Type

• 8.1. Minimally Invasive Procedures
• 8.2. Non-Invasive Procedures

9. MRI Guided Neurosurgical Ablation Market, by Procedure Objective

• 9.1. Curative Procedures
• 9.2. Palliative Procedures
• 9.3. Functional Modulation Procedures

10. MRI Guided Neurosurgical Ablation Market, by Application

• 10.1. Brain Tumors
  • 10.1.1. Glioblastoma
  • 10.1.2. Meningioma
  • 10.1.3. Metastatic Tumors
• 10.2. Chronic Pain
  • 10.2.1. Sciatica
  • 10.2.2. Trigeminal Neuralgia
• 10.3. Epilepsy
  • 10.3.1. Focal Epilepsy
  • 10.3.2. Temporal Lobe Epilepsy
• 10.4. Movement Disorders
  • 10.4.1. Dystonia
  • 10.4.2. Essential Tremor
  • 10.4.3. Parkinson's Disease

11. MRI Guided Neurosurgical Ablation Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. MRI Guided Neurosurgical Ablation Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. MRI Guided Neurosurgical Ablation Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Accuray Incorporated
• 15.2. AngioDynamics, Inc.
• 15.3. Boston Scientific Corporation
• 15.4. ClearPoint Neuro, Inc.
• 15.5. Elekta AB
• 15.6. Insightec Ltd.
• 15.7. Medtronic plc
• 15.8. Monteris Medical Inc.
• 15.9. Profound Medical Corp.
• 15.10. Siemens Healthineers AG